Search Medical Condition
Please enter condition
Please choose location from dropdown

Seo-gu, Korea, Republic of Clinical Trials

A listing of Seo-gu, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (193) clinical trials

Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)

Edoxaban is an orally administered anticoagulant that inhibits coagulation factor Xa. It has been approved by the Ministry of Food and Drug Safety (MFDS) in Korea (date: 25th, August 2015) for the: Reduction in the risk of stroke and systemic embolism in patients with non valvular atrial fibrillation (NVAF) Treatment ...

Phase N/A

0.0 miles

Learn More »

Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Primary objective of this study is to assess the efficacy of durvalumab + tremelimumab + EP treatment compared with EP in terms of overall survival and progression-free survival. All patients will be randomized in a 1:1:1 ratio in a stratified manner according to the planned platinum-based therapy for Cycle 1 ...

Phase

1.87 miles

Learn More »

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy

The purpose of this study is to determine whether Nivolumab+ chemotherapy and Nivolumab+Ipilimumab is effective in the treatment of patients with EGFR mutation, T790M negative NSCLC who failed first line (1L) EGFR TKI therapy

Phase

1.87 miles

Learn More »

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at Week 16 and long term efficacy and safety up to Week 52.

Phase

1.87 miles

Learn More »

A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

This is a Phase 1b/2, randomized, double-blind, placebo-controlled, multicenter, parallel-group, efficacy and safety study of B-701 plus docetaxel versus placebo plus docetaxel in the treatment of subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are refractory to at least one prior line of chemotherapy. ...

Phase

1.87 miles

Learn More »

Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide. In the past few decades, optimal pharmacological therapies with statins targeting LDL-cholesterol substantially reduce the risks of cardiovascular disease. However, the residual cardiovascular risk is still high, requiring need for additional preventive therapies to achieve even greater risk reduction. ...

Phase

1.87 miles

Learn More »

Second-Line Irinotecan vs. ILF for AGC

Patients with recurrent or metastatic gastric cancer can benefit from palliative chemotherapy. However, over half of patients with metastatic gastric cancer who received chemotherapy failed to achieve response and even in these responders, the duration of responses was as short as a few months. Patients with metastatic gastric cancer who ...

Phase

1.87 miles

Learn More »

Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC

Gastric cancer is the most frequently occurring malignancy in Korea, and is one of the main causes of cancer death. While treatment options for AGC have expanded in recent years to include newer agents such as taxanes, irinotecan and oxaliplatin, myelosuppression remains a problem. Recently, weekly schedule of docetaxel is ...

Phase

1.87 miles

Learn More »

Post-marketing Surveillance Study of Adalimumab (Humira ) for Non-infectious Intermediate Posterior or Panuveitis Patients

The objective of this study is to evaluate the safety and effectiveness of Humira (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.

Phase N/A

3.65 miles

Learn More »

A Randomized Multicenter Open-label Parallel-group 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

To demonstrate superiority of QVA149 (110/50 g) once daily compared to tiotropium 18 g once daily in terms of trough forced expiratory volume in 1 second (FEV1) (mean of 45 min and 15 min pre-dose) following 12 weeks of treatment in mild to moderate symptomatic COPD patients

Phase

3.78 miles

Learn More »